Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (231-240 of 512) with videos related to

Pageof 52
Sort By:
Future Oncology (London, England)|June 22, 2021
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50Renaud Descourt, Christos Chouaid, Maurice Pérol, et al.
European Radiology|May 15, 2021
Can MRI differentiate surrounding vertebral invasion from reactive inflammatory changes in superior sulcus tumor?Fadila Mihoubi Bouvier, Vincent Thomas De Montpréville, Benjamin Besse, et al.
Nature Communications|September 2, 2021
Integrin-α<sub>V</sub>-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockadeInes Malenica, Julien Adam, Stéphanie Corgnac, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2019
Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group surveyAntonin Levy, Lizza E L Hendriks, Cécile Le Péchoux, et al.
The Journal of Experimental Medicine|March 16, 2019
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancerBo Gong, Kazuma Kiyotani, Seiji Sakata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2015
Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced ToxicitiesHenrik Gréen, Johanna Hasmats, Ilya Kupershmidt, et al.
Clinical and Translational Radiation Oncology|May 19, 2023
Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancerAntonin Levy, Jonathan Khalifa, Etienne Martin, et al.
International Journal of Radiation Oncology, Biology, Physics|March 16, 2026
Tumor purity as a prognostic and predictive biomarker of postoperative radiotherapy outcomes in stage IIIA-N2 non-small-cell lung cancer: a transcriptomic analysis from the Lung ART trialWael S Zrafi, Víctor Albarrán-Artahona, Filippo G Dall'Olio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2013
Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancerEmma Pailler, Julien Adam, Amélie Barthélémy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2023
TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung CancerAlban Bessede, Florent Peyraud, Benjamin Besse, et al.
Pageof 52

Showing results (231-240 of 512) with videos related to

Sort By:
Pageof 52
Future Oncology (London, England)|June 22, 2021
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50Renaud Descourt, Christos Chouaid, Maurice Pérol, et al.
European Radiology|May 15, 2021
Can MRI differentiate surrounding vertebral invasion from reactive inflammatory changes in superior sulcus tumor?Fadila Mihoubi Bouvier, Vincent Thomas De Montpréville, Benjamin Besse, et al.
Nature Communications|September 2, 2021
Integrin-α<sub>V</sub>-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockadeInes Malenica, Julien Adam, Stéphanie Corgnac, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2019
Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group surveyAntonin Levy, Lizza E L Hendriks, Cécile Le Péchoux, et al.
The Journal of Experimental Medicine|March 16, 2019
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancerBo Gong, Kazuma Kiyotani, Seiji Sakata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2015
Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced ToxicitiesHenrik Gréen, Johanna Hasmats, Ilya Kupershmidt, et al.
Clinical and Translational Radiation Oncology|May 19, 2023
Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancerAntonin Levy, Jonathan Khalifa, Etienne Martin, et al.
International Journal of Radiation Oncology, Biology, Physics|March 16, 2026
Tumor purity as a prognostic and predictive biomarker of postoperative radiotherapy outcomes in stage IIIA-N2 non-small-cell lung cancer: a transcriptomic analysis from the Lung ART trialWael S Zrafi, Víctor Albarrán-Artahona, Filippo G Dall'Olio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2013
Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancerEmma Pailler, Julien Adam, Amélie Barthélémy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2023
TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung CancerAlban Bessede, Florent Peyraud, Benjamin Besse, et al.
Pageof 52